CHECKMATE-069: Spectacular Results With Combination Therapy

Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.

The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.

Faculty convened at an OncLive Scientific Interchange and Workshop to discuss evolving evidence-based decision-making across CSCC.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.